GREENLAND MINES LTD Total Liabilities
GREENLAND MINES LTD (GRML) had Total Liabilities of $7.11 million as of 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-17
- 2026-06-30: Liabilities $7.11M.
- 2026-03-31: Liabilities $8.27M.
- 2025-12-31: Liabilities $129.76K.
- 2025-09-30: Liabilities $145.89K.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $7.11M 10-Q · filed 2026-08-17 | |
| 2026-03-31 | $8.27M 10-Q/A · filed 2026-08-14 | |
| 2025-12-31 | $129.76K 10-Q · filed 2026-08-17 | |
| 2025-09-30 | $145.89K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $195.41K 10-Q · filed 2025-08-18 | |
| 2025-03-31 | $2.35M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $1.27M 10-K/A · filed 2026-08-14 | |
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $4.86M 10-Q · filed 2024-08-19 | |
| 2024-03-31 | $8.50M 10-Q · filed 2024-05-23 | |
| 2023-12-31 | $1.62M 10-K · filed 2025-03-31 | $8.24M 10-K · filed 2024-04-17 |
| 2023-09-30 | $7.24M 10-Q · filed 2023-11-17 | |
| 2023-06-30 | $6.73M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $69.12M 10-Q · filed 2023-05-24 | |
| 2022-12-31 | $4.93M 10-K · filed 2024-04-17 | |
| 2022-09-30 | $4.56M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $5.09M 10-Q · filed 2022-08-15 | |
| 2021-12-31 | $8.51K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |